JONATHAN D ROOT
CIK 1225480 · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.04B
Companies
9
Total Filings
74
Lifetime Open-Market Net
$9.53M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EWTX | Director | 15,625 | $43.52 | $680.0K | $250.0K | 7 | 2026-07-17 |
| OMDA | Director | 191,877 | $23.67 | $4.54M | $0 | 8 | 2026-07-07 |
| CARL | Director | 716,221 | $13.82 | $9.90M | $7.00M | 2 | 2026-06-22 |
| Inari Medical, Inc. (NARI) Delisted | Director | 0 | $79.97 | $0 | $4.81M | 14 | 2025-02-19 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | 10%+ Owner | 129,365 | $0.00 | $78 | -$4.37M | 14 | 2022-08-03 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 95,588 | $5.87 | $561.1K | $2.04M | 6 | 2022-06-13 |
| GWRE | 10%+ Owner | 11,878,173 | $170.53 | $2.03B | $0 | 1 | 2012-01-30 |
| MXL | 10%+ Owner | 3,378 | $74.98 | $253.3K | -$201.4K | 2 | 2011-05-26 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | Director | — | $10.12 | — | $0 | 3 | 2008-06-13 |
Recent Filings · Page 4 of 8
74 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-28 | EWTX | Other (J) | −3,473,543 | $0 | EDGAR |
| 2021-12-15 | ARS Pharmaceuticals, Inc. (SBTX) Delisted | Other (J) | −2,174,179 | $0 | EDGAR |
| 2021-12-06 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −8,113 | -$46.1K | EDGAR |
| 2021-12-01 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −72,418 | -$475.4K | EDGAR |
| 2021-11-26 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −56,425 | -$414.0K | EDGAR |
| 2021-11-22 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −50,169 | -$407.4K | EDGAR |
| 2021-11-17 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −23,625 | -$221.5K | EDGAR |
| 2021-11-12 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −86,802 | -$917.0K | EDGAR |
| 2021-10-08 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-21 | ARS Pharmaceuticals, Inc. (SBTX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.